Each tablet contains: Lomefloxacin hydrochloride equivalent to lomefloxacin 400 mg.
Lomax is indicated for the treatment of the following infections when caused by susceptible microorganisms:
Acute bacterial exacerbation of chronic bronchitis caused by Haemophilus influenzae or Moraxella catarrhalis.
Uncomplicated urinary tract infections (cystitis) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Staphylococcus saprophyticus.
Complicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Citrobacter diversus, or Enterobacter cloacae.
Prophylactically, Lomax is indicated pre operatively in patients undergoing transurethral surgical procedures or transrectal biopsy to reduce the incidence of urinary tract infections.
Hypersensitivity to the fluoroquinolones.
Should not be given to pregnant women, nursing mothers, children, or growing adolescents.
History of seizures, impaired renal function, photosensitivity.
(For more information see insert leaflet)
Some minor side effects may be experienced by patients receiving lomefloxacin, such as nausea, headache, photosensitivity, dizziness, and diarrhea. These side effects are mostly mild in severity and transient in nature.
Dosage and Administration
Lomax tablets should be swallowed with a full glass of water without regard to meals.
Acute bacterial exacerbation of chronic bronchitis: one tablet once daily for 10 days.
Treatment of Urinary Tract Infections
Complicated infections: one tablet once daily for 14 days.
Uncomplicated infections due to Escherichia coli: one tablet once daily for 3 days.
Uncomplicated infections due to Klebsiella pneumoniae, Proteus mirabilis, or Staphylococcus saprophyticus: one tablet once daily for 10 days.
Prophylaxis of Urinary Tract Infections Transurethral surgery: one tablet as a single dose 2 – 6 hours before the start of surgery.
Transrectal biopsy: one tablet as a single dose 1 – 6 hours before the start of surgery.
NOTE: Patients with renal function impairment may require dosage reduction based on the rate of creatinine clearance.
t: 5, 10.